Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Liabilities: 2014-2023

Historic Total Liabilities for Aytu Biopharma (AYTU) over the last 10 years, with Jun 2023 value amounting to $97.1 million.

  • Aytu Biopharma's Total Liabilities fell 0.92% to $100.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $100.7 million, marking a year-over-year decrease of 0.92%. This contributed to the annual value of $97.1 million for FY2023, which is 4.06% up from last year.
  • Per Aytu Biopharma's latest filing, its Total Liabilities stood at $97.1 million for FY2023, which was up 4.06% from $93.3 million recorded in FY2022.
  • In the past 5 years, Aytu Biopharma's Total Liabilities ranged from a high of $128.1 million in FY2021 and a low of $27.6 million during FY2019.
  • Moreover, its 3-year median value for Total Liabilities was $97.1 million (2023), whereas its average is $106.2 million.
  • As far as peak fluctuations go, Aytu Biopharma's Total Liabilities skyrocketed by 261.90% in 2019, and later declined by 27.15% in 2022.
  • Yearly analysis of 5 years shows Aytu Biopharma's Total Liabilities stood at $27.6 million in 2019, then soared by 110.90% to $58.3 million in 2020, then spiked by 119.81% to $128.1 million in 2021, then decreased by 27.15% to $93.3 million in 2022, then climbed by 4.06% to $97.1 million in 2023.